CSPC PHARMA (01093.HK): SYS6090 granted FDA Fast Track designation for MSS/pMMR metastatic colorectal cancer

NewTimeSpace News: On 26 August 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) announced that SYS6090 (JMT108), a first-in-class PD-1/IL-15 bispecific fusion protein developed by the Group, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) who have progressed after prior standard systemic therapy.

The announcement stated that colorectal cancer (CRC) remains a significant public health challenge in the United States, being the third most common cancer and the second leading cause of cancer-related death; according to statistics from the Surveillance, Epidemiology, and End Results (SEER) program of the U.S. National Cancer Institute, the 5-year survival rate for patients with distant metastatic CRC is approximately 17%, while the median overall survival for MSS/pMMR mCRC patients who have received three or more lines of therapy is typically still less than 12 months, representing a substantial unmet clinical need. MSS/pMMR mCRC is considered a typical "cold" tumor with limited response to standard immunotherapy.

SYS6090 is a bispecific fusion protein that simultaneously blocks PD-1 and activates the IL-15 signaling pathway, with a specifically designed asymmetric structure that precisely directs IL-15 activity in a PD-1-dependent manner, possessing the potential to selectively remodel the resistant or immunologically "cold" tumor microenvironment and activate exhausted effector cells, while minimizing immune-related toxicity. The data supporting the Fast Track designation include preclinical study results and data from the Phase I clinical study currently being conducted concurrently in China and the United States. The FDA's Fast Track designation recognizes the product's potential to treat serious or life-threatening diseases and will help accelerate its development and review process in the United States and globally.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.